RxDoctor Payments DataLook up a doctor →

David Farzan, MD

Family Medicine · Lawrence, MANPI 1093719924

Payments from drug & device makers

$23,443in general payments, 2019–2025

Across 1,146 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$3K
  • Pfizer$2K
  • Lilly USA, LLC$2K
  • Novo Nordisk$2K
  • GSK$1K
  • plus $11K from 43 others

What the payments were for

  • Speaking & faculty fees$1000%
  • Food & beverage$23,30399%
  • Education$400%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,443 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$177,489
Medicare patients
434
Services billed
2,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin180$195,708
TrulicityDulaglutide144$190,146
EliquisApixaban110$116,288
FarxigaDapagliflozin Propanediol85$90,316
OzempicSemaglutide64$61,692
MounjaroTirzepatide33$45,896
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$31,853
XareltoRivaroxaban14$21,855
KerendiaFinerenone14$18,056
EntrestoSacubitril/Valsartan15$11,483
Albuterol Sulfate HfaAlbuterol Sulfate209$7,634
Atorvastatin Calcium597$7,375
Rosuvastatin Calcium257$6,417
SymbicortBudesonide/Formoterol Fumarate17$6,179
Omeprazole331$5,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,775$236,043177 claims
Boehringer IngelheimJardiance$929$195,708180 claims
PfizerEliquis$2,227$116,288110 claims
AstraZenecaFarxiga, Symbicort$2,662$96,495102 claims
Novo NordiskOzempic$1,609$61,69264 claims
GSKTrelegy Ellipta, Incruse Ellipta$1,121$35,93545 claims
Johnson & JohnsonXarelto$727$21,85514 claims
BayerKerendia$990$18,05614 claims
NovartisEntresto$334$11,48315 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$2,807187 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Lawrence

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →